StocksMedium•14 October 2026•
1 min read
Vanda Pharmaceuticals Phase III Trial for Social Anxiety Fails
Key Facts
1Vanda Pharmaceuticals' VQW-765 failed to meet the primary endpoint in a Phase III clinical trial for social anxiety disorder.
Vanda Pharmaceuticals' VQW-765 failed to meet the primary endpoint in a Phase III clinical trial for social anxiety disorder. Investing.com reported that the clinical trial results did not demonstrate a statistically significant improvement compared to the placebo, leading to a failure in the drug's development milestone.
The failure of the Phase III trial represents a significant setback for the biotech firm, as the results failed to prove the required efficacy for the anxiety treatment. These developments occur as the sector faces challenges regarding R&D valuations following advanced trial failures, amid a broader economic context on October 14, 2026.